We have also shown that ex vivo IFNγ treatment enhanced in a BCL6-dependent manner the cluster formation of imatinib-treated primary human CD34+ CML stem/progenitor cells. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.